Get startedLog in
    Picture of Chosa Oncology AB logo

    CHOSA — Chosa Oncology AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: RhoVac: Signs Of Delays In Ongoing Clinical Phase IIb Study With Drug Candidate RV001 Due To COVID-19

    Picture of Chosa Oncology AB logoChosa Oncology AB
    02/04/2020 09:54
    April 2 (Reuters) - RhoVac AB  RHOVAC.TE :
    * COVID-19 RELATED DELAYS IN THE ONGOING PHASE IIB-STUDY ARE
EXPECTED TO BE MANAGED WITH EXISTING FUNDING
    * ON CORONAVIRUS: NOW SEEING SIGNS OF DELAYS IN ONGOING
CLINICAL
PHASE IIB STUDY WITH DRUG CANDIDATE RV001 IN PROSTATE CANCER,
DUE TO COVID-19 PANDEMIC
    * ESTIMATES THAT EXISTING FINANCING WILL COVER EXPECTED
DELAYS
    * COMPANY BELIEVES THAT DELAYS THAT CAN BE FORESEEN NOW ARE
COVERED BY EXISTING FINANCING
    * WE HAVE FUNDING THAT IS EXPECTED TO COVER COMPANY'S NEEDS
THROUGH TO SECOND HALF OF 2022

Source text for Eikon:  ID:nWkr1tCKGJ 
Further company coverage:  RHOVAC.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

    Recent news on Chosa Oncology AB

    See all news